PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1330154-11	1992	Preincubation with the PKC inhibitor Ro-31-8220 abolished both TPA- and vasopressin-stimulated [3H]-PtdBuOH, suggesting that the intermediate activation of protein kinase C is involved in the regulation of PLD by vasopressin.	Ro 31-8220	37-47	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	206-209	
7544577-7	1995	Ro-31-8220 additionally inhibited A23187-stimulated PLD activity, indicating that Ca2+ activation of PLD also occurs via a protein kinase C-dependent pathway.	Ro 31-8220	0-10	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	52-55	
7544577-7	1995	Ro-31-8220 additionally inhibited A23187-stimulated PLD activity, indicating that Ca2+ activation of PLD also occurs via a protein kinase C-dependent pathway.	Ro 31-8220	0-10	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	101-104	
1330154-13	1992	Pretreatment of the A10 VSMC with Ro-31-8220 (100 microM) also potentiated vasopressin-stimulated Ins(1,4,5)P3 mass formation.Therefore stimulation of PKC may have opposing roles in the regulation of agonist activation of PLC and PLD.7.	Ro 31-8220	34-44	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	230-233	
11563985-5	2001	Ras-induced activation of PLD was resistant to the protein kinase C (PKC) inhibitor GF109203X, which preferentially affects conventional- and novel-type PKCs, but sensitive to Ro-31-8220, which inhibits atypical PKCs more effectively.	Ro 31-8220	176-186	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	26-29	
1371383-3	1992	In contrast, the protein kinase C inhibitor Ro-31-8220 inhibited phorbol 12,13-dibutyrate- but not fMet-Leu-Phe-stimulated PLD activity, arguing against the involvement of protein kinase C in the receptor-mediated activation of PLD.	Ro 31-8220	44-54	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	123-126	
10614786-7	1999	RO 31-8220, a specific inhibitor of PKC, reduced PMA-induced PLD activity by 80% in intact HL60 granulocytes but enhanced fMLP-stimulated PLD activity by 60%.	Ro 31-8220	0-10	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	61-64	
11749856-7	2001	Pretreatment of cells with PKC inhibitors Ro-31-8220, staurosporine, and rottlerin increased the propranolol-induced PLD.	Ro 31-8220	42-52	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	117-120	
11419696-4	2001	PKC inhibitors Ro-31-8220 and bisindolylmaleimide I, showed the same inhibitory effects on the BK-stimulated increase of PLD activity, indicating a role of PKC in this activation process.	Ro 31-8220	15-25	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	121-124	
10614786-7	1999	RO 31-8220, a specific inhibitor of PKC, reduced PMA-induced PLD activity by 80% in intact HL60 granulocytes but enhanced fMLP-stimulated PLD activity by 60%.	Ro 31-8220	0-10	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	138-141	
9428812-9	1998	Ro-31-8220 and bisindolylmaleimide I, inhibitors of protein kinase C, blocked activation by PLD by both PMA and LPA.	Ro 31-8220	0-10	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	92-95	
9395070-0	1997	Ro31-8220 inhibits protein kinase C to block the phorbol ester-stimulated release of choline- and ethanolamine-metabolites from C6 glioma cells: p70 S6 kinase and MAPKAP kinase-1beta do not function downstream of PKC in activating PLD.	Ro 31-8220	0-9	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	231-234